Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Early data on efficacy in patients with anxiety and demoralization are promising. She’s also a leader in the Cancer Prevention and Control Center at the University of Colorado there at the Cancer Center.
Let's personalize your content